Bausch + Lomb Corporation

NYSE:BLCO

Medical - Instruments & Supplies

Healthcare
$20.95 +0.27%

+$0.04 today

Market cap
$7.49B
Beta
0.57
P/E (TTM)
-24.2
EPS (TTM)
-$0.62
52W Low $11.58High $18.92

Volume 0.51M

Average 0.46M

BLCO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Bausch + Lomb CorporationNYSE: BLCO

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $38M rose 26.7% year over year, ahead of the -33.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 11.8% from the prior quarter. Over 3 fiscal years it compounded at +33.9% a year.

Context

  • Stock-based compensation amounted to 2.9% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +26.7% holds above the trailing-twelve-month pace of -33.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$38M+11.8% QoQ
Last fiscal yearDec 2025
$149M+62.0% YoY
LTMJun 2026
$72M-33.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.7%——
1 year+62.0%——
3-year CAGR+33.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
149M USD
Year-over-year change
+62.0%
4-year CAGR
+24.5%

Stock-Based Compensation vs competitors

How BLCO compares with its peers on the latest reported figures

  • BLCO's LTM Jun 2026 stock-based compensation of $72M is the 6th largest of the 10 companies compared; the peer median is $75.19M.
  • Its year-over-year change of -33.9% is the lowest of 10, against a peer median of +7.5%.
  • Stock-based compensation amounts to 1.4% of revenue for BLCO, versus a peer median of 9.1%.
BLCO Competitors Peer median
Stock-Based Compensation for BLCO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCVXVaxcyte, Inc.LTM Jun 2026$188.47M +66.5%+80.4%—
TGTXTG Therapeutics, Inc.LTM Sep 2026$88.18M +44.6%+49.9%9.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$84.66M +15.0%-12.3%8.4%
GKOSGlaukos CorporationLTM Jun 2026$80.22M +36.6%+17.9%13.1%
OSCROscar Health, Inc.LTM Jun 2026$75.19M -27.9%-7.9%0.5%
BLCOBausch + Lomb CorporationLTM Jun 2026$72M -33.9%+33.9%1.4%
CRSPCRISPR Therapeutics AGLTM Sep 2026$69.68M -8.8%-9.5%276.8%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$68.15M +7.5%-4.5%15.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$45.39M +5.4%+34.1%2.8%
TFXTeleflex IncorporatedLTM Jun 2026$20.21M -33.5%—0.8%
Peer median (excluding BLCO) $75.19M+7.5%+6.7%9.1%

Competitors are the stored peer set for BLCO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income193M15M(248M)(305M)(352M)
Depreciation & Amortization415M379M382M436M421M
Deferred Income Tax116M(90M)(10M)(10M)(32M)
Stock-Based Compensation62M62M74M92M149M
Change in Working Capital28M(19M)(287M)(87M)18M
Accounts Receivables(107M)(95M)(121M)(227M)(148M)
Inventory(15M)(106M)(264M)(147M)38M
Accounts Payables163M189M245M126M108M
Other Working Capital(13M)(7M)(147M)161M20M
Other Non-Cash Items59M(2M)72M106M79M
Operating Cash Flow873M345M(17M)232M283M
Capital Expenditures(193M)(175M)(181M)(291M)(349M)
Acquisitions (Net)(16M)45M(1.94B)00
Purchases of Investments(19M)(62M)(17M)(12M)(11M)
Sales of Investments14M22M16M14M8M
Other Investing Activities0(45M)14M(123M)(103M)
Investing Cash Flow(214M)(215M)(2.11B)(412M)(455M)
Debt Repayment28M2.46B2.12B201M249M
Common Stock Issued00000
Common Stock Repurchased000(12M)0
Dividends Paid00000
Other Financing Activities(740M)(2.38B)(37M)(11M)(24M)
Financing Cash Flow(712M)81M2.08B178M225M
Effect of Forex Changes(8M)(8M)2M(16M)28M
Net Change in Cash(61M)203M(46M)(18M)81M
Free Cash Flow680M170M(198M)(59M)(66M)

Bausch + Lomb Corporation

NYSE:BLCO

Intrinsic Alpha fair value

Locked

Current Price

$20.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.